Skip to content
PHARMACEUTICAL PREPARATIONS · LARGE CAP

Crinetics Pharmaceuticals, Inc. CRNX

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.7M
▲ 640.7% YoY
$-465.3M
$-383.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our lead product, PALSONIFY (paltusotine), is the first once-daily, oral treatment approved by the FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Crinetics’ understanding of these hormonal pathways and the GPCRs that control them coupled with our expertise in developing nonpeptides with specific pharmacologies allows us to create new molecules with the chance to improve the lives of patients with metabolic diseases. Our mission is to build the world’s leading endocrine company that pioneers new therapeutics to help patients better control their disease and improve their daily lives. As of February 13, 2026, we had 594 full-time employees, 150 of whom have a Ph.D. or M.D.

Written from the business description in Crinetics Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 7.7M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.7 · Net income -465.3
-200M-400M
2016201920222025
Compound annual growth
+17.6%
+155.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +155.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -6714.8% · Net ·
-50000%-100000%
201620202025
ROE
FY2025 · ROE -40.2%
-20%-40%
201620202025
Three returns, three denominators.

Each USD of equity lost 40 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -383.7
-150M-300M
201620202025

Total assetsUSD 1.1B
EquityUSD 992.1M
CashUSD 101.5M
Current ratio12.32×

Equity funds 88% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CRNX, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.5−0.3−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.5−0.3−0.2−0.2−0.1−0.1−0.1−0.0◌◌
Income tax $B0.00.00.00.00.00.00.00.00.00.0
Net income $B−0.5−0.3−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.4−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EPS, diluted $−4.95−3.69−3.69−3.15−2.80−2.42−2.09−2.23−6.68−5.96
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−40.2−32.0−50.2−50.6−43.0−51.6−36.4———
Shares out B0.100.090.070.050.050.030.020.000.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 38 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 16 checks were skipped: cost of revenue is not tagged before 2023. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2016

Share this section

Download image